Weight Watchers has appointed Stephen Bye as president and chief executive officer, effective this autumn. Bye previously served as CEO of Ookla, a connectivity intelligence company, where he transformed the subscription business and improved profitability whilst leading multiple acquisitions. Gene Davis, chairman of Weight Watchers' board, cited Bye's track record of growing subscription businesses and creating shareholder value. The board conducted an extensive search prioritising proven CEO leadership and experience in consumer subscription businesses. Bye brings over 30 years of leadership experience in consumer technology businesses. He has held senior roles at DISH Network, Connectivity Wireless, C Spire, and Sprint, where he served as chief technology officer. Weight Watchers is building an integrated weight health platform combining behavioural approaches, clinical care, and access to GLP-1 medications with technology-driven personalisation.

WeightWatchers reported Q2 revenues of $162.3 million, down 14.2% year-on-year but exceeding analyst expectations by 2%. The wellness company beat EPS estimates but missed EBITDA projections in what was deemed a satisfactory quarter. Despite the relatively good results, WeightWatchers delivered the weakest full-year guidance update among nine consumer discretionary specialised consumer services stocks tracked. The sector as a whole underperformed in Q2, with revenues missing consensus estimates by 0.7%. The market reacted negatively to WeightWatchers' outlook. Shares fell 8.4% following the earnings announcement and currently trade at $14.12. Consumer discretionary specialised consumer services stocks have declined 4.6% on average since their latest earnings results.

WeightWatchers reported second-quarter revenue of $162.3 million, beating analyst estimates of $159.1 million despite a 14.2% year-on-year decline. The company posted earnings per share of $1.41, significantly above the $0.67 estimate. Management highlighted a strategic shift towards higher-value membership tiers and clinical offerings, with growth in Core+ and Med+ subscribers offsetting declines in traditional behavioural segments. Interim Chief Operations Officer Jonathan Volkmann noted the company's approach combines FDA-approved GLP-1 medications with expert guidance. The company reaffirmed full-year revenue guidance of $627.5 million and EBITDA guidance of $110 million. Operating margin fell to 8.1% from 28.1% in the prior year quarter. No analyst question-and-answer session occurred during the earnings call.